Aflibercept for the treatment of neovascular glaucoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1442-9071|43|9|803-807

ISSN： 1442-6404

Source： CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol.43, Iss.9, 2015-12, pp. : 803-807

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age‐related macular degeneration patients

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment outcomes of ziv‐aflibercept for treatment‐naïve polypoidal choroidal vasculopathy

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e258-e259

John Wiley & Sons Inc

Access to resources Recommend Favorite

One‐year treatment outcomes of ziv‐aflibercept for treatment‐naïve macular oedema in branch retinal vein occlusion

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e256-e257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Short‐term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor‐A and pigment epithelium‐derived factor in neovascular glaucoma

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 5, 2015-07 ,pp. : 415-421

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite